Early use of erenumab in US real-world practice - Alina Bogdanov, Victoria Chia, Mark Bensink, Robert Urman, Lauren Fischer, Soeren Rasmussen, Christine Szekely, Lee Kallenbach, 2021

Source : https://journals.sagepub.com/doi/full/10.1177/25158163211020419

Background: Erenumab, a monoclonal antibody (mAb) developed to block the calcitonin gene-related peptide (CGRP) receptor, is approved for the prevention of migraine in adults. This retrospective observational study sought to describe early real-world use of erenumab. This study used the Practice Fusion ambulatory Electronic Health Record database, which represents approximately 6% of ambulatory care among primary care and specialist practices in the United States.